Trial Summary
What is the purpose of this trial?The primary objectives of this study are to assess the safety, tolerability, and efficacy of ABP-671 in lowering serum uric acid (sUA) in participants with gout who roll over from Study ABP-671-301 after they complete the double-blind 28-week Treatment Period of Part 1 (Phase 2b) or Part 2 (Phase 3).
Eligibility Criteria
This trial is for people with gout who finished the initial 28-week treatment in Study ABP-671-301 and are doing well on the medication. They can't join if they have new health or mental issues, plan to get pregnant or breastfeed soon, or can't take colchicine or naproxen.Exclusion Criteria
I cannot or do not want to take colchicine or naproxen.
Participant Groups
The study tests the safety and effectiveness of a drug called ABP-671 in lowering uric acid levels in gout patients. It's an extension of a previous study where participants continue with their current treatment from that study.
2Treatment groups
Experimental Treatment
Active Control
Group I: ABP-671Experimental Treatment1 Intervention
Group II: AllopurinolActive Control1 Intervention
Find A Clinic Near You
Research locations nearbySelect from list below to view details:
Access Research InstituteBrooksville, FL
DelRicht Research of GulfportGulfport, MS
Center for Clinical Trials of SacramentoSacramento, CA
Century Research LLCMiami, FL
More Trial Locations
Loading ...
Who is running the clinical trial?
Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.Lead Sponsor